MarketsNotableSingle-sourceDeveloping
5.1
Citius Pharmaceuticals receives Nasdaq delisting notice for failure to meet minimum bid price
SEC EDGAR 8-K FilingsLO·US·3 days ago
Breeze Acquisition Corp. II has filed an 8-K disclosing a notice of delisting or failure to satisfy continued listing standards. The filing indicates a potential regulatory or compliance issue regarding the company's exchange status, though specific details on the underlying cause remain to be clarified in subsequent disclosures.